The Week in Review: July 14 – July 21, 2017

Friday, July 21, 2017 News Recap 1) Vosevi Approved in US – Under Review in Canada Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....

Know Your Status — Get Tested

Know Your Status — Get Tested. That’s the message for those born between 1945 and 1975. Three out of four Canadians who have hepatitis C (HCV) fall within this age bracket. Del Grimstad is one of those, but has successfully treated the virus that mostly attacks the liver, but can also cross the brain barrier. “Which we’ve suspected for many years, but they finally got proof of it,” said Grimstad, a harm reduction worker at AIDS Vancouver Island (AVI) w

HCV in Banff: A report from Del Grimstad, Vice-President of HepCBC, and HepCBC representative to AHC

Starting fresh from a two day training session in Victoria I awoke at 4 am in order to be at the airport at 5 am for a 6 am flight to Calgary, arrived at 8:40 am (local) and left by bus to Banff around 10 am. Arrival in Banff coincided with the start of my first meeting with Action Hepatitis Canada (AHC). The meeting was great and a lot was accomplished by the wrap-up for the day around 8:30 pm. AHC had a lot on their plate for the event, starting w...